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Genome-wide mapping for clinically relevant 
predictors of lamotrigine- and phenytoin-induced 
hypersensitivity reactions 
Carbamazepine (CBZ), lamotrigine (LTG) and 
phenytoin (PHT), among a class of antiepileptic 
drugs (AEDs) involved in sodium-channel 
modulation, are three of the leading first-line 
treatments for epilepsy. CBZ and PHT are 
among the earliest AEDs and are typically used 
to control partial seizures. LTG is well established 
as an effective drug for partial seizures, primary- 
and secondary, generalized tonic–clonic seizures, 
as well as for the treatment of Lennox–Gastaut 
syndrome. All of them have also been found to 
be useful in other conditions, such as bipolar 
disorder and trigeminal neuralgia. 
Despite being highly effective, CBZ, LTG 
and PHT are associated with cutaneous adverse 
drug reactions (cADRs), which encompasses a 
mild maculopapular eruption (MPE), a more 
serious hypersensitivity syndrome (HSS) with 
liver and other internal organ involvement to 
the potentially fatal Stevens–Johnson syndrome 
(SJS) and/or toxic epidermal necrolysis (TEN). 
The highest rate of AED-related cADRs occurs 
with CBZ, LTG and PHT, each of them are 
structurally related through an aromatic ring, 
yet each are targeted towards different seizure 
profiles [1].
CBZ has been the focus of numerous 
genetic studies, especially since the discovery 
of the genetic marker HLA-B*1502 as a strong 
predictor for CBZ-induced SJS/TEN in sub-
jects of Han Chinese ancestry [2]. Studies by 
the same group have also shown that the HLA-
B*1502 association with SJS/TEN extends to 
PHT and oxcarbazepine (OXC) [3]. Further 
research has illustrated that HLA-B*1502 
also has a predictive ability for individuals of 
Malaysian, Indian, Thai and other Asian eth-
nicity [4–6]. The extent to which LTG-induced 
SJS/TEN associates with HLA-B*1502 remains 
to be elucidated and requires further investiga-
tion. As noted by Shi and colleagues, of the 
seven reported cases of LTG-induced SJS/TEN, 
three were positive for HLA-B*1502 [7]. To date, 
evidence from studies in Thai and Han Chinese 
populations suggests that there is no such asso-
ciation with the milder MPE phenotype trig-
gered by either PHT or LTG [5,7,8]. However, 
a recent study has indicated that HLA-B*1502 
may have predictive value for OXC-induced 
MPE [9]. Although the authors only studied 
nine OXC-induced MPE cases, four of these 
were positive for HLA-B*1502, a significant 
observation when compared with population 
controls. These observations are particularly 
interesting given the close structural homology 
between OXC and CBZ.
However, the genetic association with 
HLA-B*1502 appears to be limited to Asian 
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populations. Studies in subjects of European 
ancestry have indicated that HLA-B*1502 is 
not present in CBZ–SJS patients of European 
descent [10,11]. This is not surprising considering 
the decreasing frequency of the HLA-B*1502 
allele from a high frequency of 6% in Asia to 
virtually absent in Europe [12]. 
A 2006 study by Hung and colleagues 
reported an association between CBZ-induced 
MPE with HLA-A*3101 among patients of 
Han Chinese descent [13]. Using a genome-
wide approach, we identified HLA-A*3101 as a 
clinically relevant predictor for the full spectrum 
of CBZ-induced hypersensitivity reactions in 
Europeans, while a separate study by Ozeki and 
colleagues reported a significant association 
with HLA-A*3101 and CBZ-induced cADRs in 
a Japanese population [14,15]. The relationship 
between HLA-A*3101 and CBZ-induced HSS 
has now also been reported in patients of  Korean 
descent [16].
Here we set out to investigate whether 
HLA-A*3101 or any other common genetic variant 
identified through genome-wide association 
studies (GWAS) may act as a predisposing factor 
for two of the other common AEDs known to 
cause cADRs, namely LTG and PHT. 
Materials & methods
 n Case subjects
We obtained approval for this study from the 
local research ethics committees of each site. 
Written, informed consent was obtained from 
all subjects prior to participation. Patients were 
recruited through centers affiliated with the 
EPIGEN Consortium; namely Duke University 
(NC, USA), University College London 
(London, UK), Université Libre de Bruxelles 
(Brussels, Belgium) and the Royal College of 
Surgeons in Ireland with Beaumont Hospital 
(Dublin, Ireland).
All patients were of European ancestry as 
determined by self-report and genetic-marker 
ana lysis. Cases were separated according to the 
causal drug and then phenotyped into distinct 
hypersensitivity states of MPE, HSS and 
SJS based on the extent and severity of their 
ADR and using disease criteria, as previously 
reported [14]. In total, there were 46 ADR cases 
relating to LTG, of which 42 were MPE cases, 
three were HSS and one was SJS. Of the 44 PHT-
induced ADR cases, 40 were MPE cases and 
four were HSS cases. There were four patients 
who experienced MPE with both drugs on 
separate occasions and were thus included in 
each set of analyses. Given the low numbers of 
HSS and SJS patients and the evidence that a 
common marker may exist for all phenotypes 
(as evidence would suggest for HLA-A*3101 and 
CBZ-induced cADRs) we analyzed all cases 
together as drug-specific cADR groups. 
 n Control subjects
The control group consisted of a homogeneous 
subgroup of 1296 subjects from the 1958 British 
birth cohort that were selected by principal 
component ana lysis of GWAS. Controls were 
unscreened for AED-related ADRs. 
 n Genome-wide ana lysis
Genome-wide data across >600,000 SNPs were 
available for 34 LTG and 42 PHT cases and all 
1296 population control subjects. Genotyping 
for all cases was performed with the Illumina® 
Human610–610K Quad platform at the Duke 
University Center for Human Genome Variation 
(NC, USA). We removed subjects with a 
genotyping failure rate below 95%, SNPs with 
low minor allele frequency (<2%), those failing 
the Hardy–Weinberg equilibrium and any that 
had missing genotype information in >10% of 
all subjects. 
Table 1. Distribution of HLA-A*3101 among lamotrigine and phenytoin case 
subjects compared with population control subjects.
HLA-A*3101 Lamotrigine–cADR cases Phenytoin–cADR cases Controls
Carriers (n; %) 2 (4.35%) 2 (4.55%) 72 (5.56%)
Noncarriers (n; %) 44 (95.65%) 42 (95.45%) 1224 (94.44%)
Total subjects (n) 46 44 1296
p-value 0.698 0.746
Odds ratio (95% CI) 0.756 (0.183–3.129) 0.791 (0.191–3.277)
Relative risk for 80% 
power
2.204 2.229
HLA-A*3101 was found at a low average frequency of 4.45% across all cADR cases and at 5.56% in our population 
controls, which is comparable with reported European population datasets [23]. 
cADR: Cutaneous adverse drug reaction.
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 n Imputation of HLA alleles
We imputed classic HLA alleles for all cases and 
controls using MACH 1.0 [17]. This method 
has been validated as an accurate method 
for imputing HLA subtypes in our cohort as 
described previously [14]. The HLA-typed 1958 
British birth cohort constituted the reference 
population for imputation. For those samples for 
which GWAS data were not available we used 
PCR with sequence-specific primers to determine 
the presence of HLA-A*3101. The PCR conditions 
were as follows: the forward primer sequence 
was 5´-GATAGAGCAGGAGAGGCCT-3 ,´ 
r e v e r s e  p r i m e r  s e q u e n c e  w a s 
5´ -AGCGCAGGTCCTCGTTCAA-3´ and the 
cycling parameters were 95°C for 3 min, five cycles 
of 95°C for 15 s, 70°C for 15 s and 72°C for 30 s, 
two cycles of 95°C for 15 s, 65°C for 15 s and 72°C 
for 30 s, four cycles of 95°C for 15 s, 55°C for 
1 min and 72°C for 2 min, finally 72°C for 7 min.
 n Statistical analysis
Statistical analyses were performed using PLINK 
(version 1.05) [18] and EIGENSTRAT [19] 
software packages. For the GWAS, we applied 
logistic regression (using an additive model) to 
each of the cADR case groups in turn versus the 
1958 British birth cohort controls. We adjusted 
for population stratif ication by including 
significant principal components (generated 
using EIGENSTRAT) as covariates in the 
logistic-regression model and used a p-value of 
less than 5.0 × 10-8 as a threshold for genome-
wide significance. Supplementary Figure S1 (see online, 
www.futuremedicine.com/doi/suppl/10.2217/
PGS.11.165) for a plot of the first and second 
principal components between cases and 
controls. Post-GWAS annotation ana lysis was 
performed with WGAViewer [20]. We calculated 
study power using the program Power for 
Genetic Association Analyses [21]. We estimated 
the relative risk (RR) required for 80% power to 
detect an allelic association (under an additive 
disease model) with the following parameters: a 
prevalence of 10% of the ADR in the population, 
a minor allele frequency of 5%, an experiment-
wide a level of 0.05 and the assumption that a 
genetic marker is causal or in complete linkage 
with the causal variant. 
Results
 n HLA-A*3101 as a predictor of LTG- 
and PHT-induced cADRs
table 1 illustrates the results of HLA-A*3101 
genotyping in LTG- and PHT-induced cADR 
cases and population controls. The allele 
does not appear to be enriched in any of the 
cADR patient groups. For each of the analyses 
considered, our power calculations indicate that 
we had reasonable power to detect effect sizes of 
clinical relevance (RR >2).
 n GWAS results
We next conducted a GWAS for each of the 
drug-specific cADR groups as well as a total 
combined case cohort. The results of the 
logistic regression analyses are depicted as 
Manhattan and quantile–quantile plots in 
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Figure 2. Quantile–quantile plot of the association results. Quantile–quantile 
plots of p-values from genome-wide association studies of (A) lamotrigine, 
(B) phenytoin and (C) total drug-induced cutaneous adverse drug reactions vs 
controls calculated using logistic regression and including significant EIGENSTRAT 
axes as covariates. The expected chi distribution is represented along the x-axis, 
while the observed chi distribution is represented along the y-axis. Figure generated 
in WGAViewer. 
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FigureS 1 & 2. The ten most significant markers 
from the logistic regression analyses are listed 
in Supplementary tableS S1–S3. We did not detect any 
variants satisfying our threshold for genome-
wide significance (p-value of 5.0 × 10-8), nor 
did we observe any significant deviations from 
the expected distribution in quantile–quantile 
plots (results shown in FigureS 1 & 2). From power 
calculations (Figure 3) we estimated that we had 
80% power to detect a variant with a minor 
allele frequency >10% and a RR >2.5 when 
considering all cases together. We feel this RR 
is within the realm of clinical relevance.
Discussion
The results presented here suggest that HLA-
A*3101 is not a clinically relevant predictor of 
cADRs caused by LTG and PHT in populations 
of European descent. 
It has been shown in previous studies by 
ourselves and others that HLA-A*3101 is a 
strong predictor for the clinical spectrum of 
CBZ-induced hypersensitivity and we reported 
an odds ratio of 8.33 for CBZ-induced MPE 
for a population of European descent, while the 
corresponding value for a population of Japanese 
descent was 10.8 [15].
We calculated that the current study had 80% 
power to detect a RR of 3.27 for cADRs based 
on a frequency of 5% for HLA-A*3101, which 
gives this study ample power to detect an effect 
size similar to that reported previously for CBZ-
induced MPE. If HLA-A*3101 is a predictor for 
either LTG- or PHT-induced cADRs, we were 
well powered to detect it. Of the 44 cases of 
PHT-induced cADRs, only two were positive for 
HLA-A*3101. Similarly, only two of the 46 cases 
of LTG-induced cADRs were positive for the 
allele. Incidentally, one of the subjects positive 
for HLA-A*3101 in the LTG case group had a 
historical report of a rash with CBZ. 
Although we included HSS and SJS, the 
overwhelming majority of cases were of the MPE 
type. Given the small number of HSS and SJS 
cases, we pooled all cases into a single group of 
hypersensitivity ADR cases per drug for a better 
powered genome-wide ana lysis. We chose to 
analyze all cases together as cADR groups as we 
did not have enough subjects to run a powered 
GWAS for HSS or SJS alone. The GWAS results 
remain negative when the HSS and SJS cases are 
removed. Further studies of PHT- and LTG-
induced HSS and SJS in larger patient cohorts 
is warranted, especially given that the genetic 
predictors (e.g., HLA-B*1502) can be selective 
for a given hypersensitivity reaction [5,13,22], and 
the effect size correlates with the severity of the 
phenotype across the hypersensitivity spectrum 
(as appears to be the case for HLA-A*3101 and 
CBZ [14,16]). 
Our GWAS results are not suggestive of 
a common, clinically relevant predictor of 
LTG- or PHT-induced cADRs in a European 
population. None of the variants tested satisfied 
the GWAS significance threshold, nor was there 
any clear biological candidate from within the 
pool of the most significant SNPs (Supplementary 
tableS S1–S3). Our study was powered to detect a 
variant of minor allele frequency >10% carrying 
a clinically relevant genetic effect (RR > 2.5). We 
recognize that sample size is a major limitation 
of our study. This has limited our ana lysis to 
effect sizes in the realm of clinical relevance (for 
cADRs) and has prevented us from studying 
SJS/TEN specifically. We also cannot rule 
out genetic variants conveying smaller effects 
(RR <2.5) or rare variants of small or large effect, 
which were not captured by our GWAS chip. 
With the increased availability of whole-
exome and whole-genome sequencing, it should 
become possible and more affordable to identify 
rare variants not captured through GWAS. 
Discovering these genetic markers would 
further the understanding of the functional role 
of HLA in drug response, as well as helping 
clinicians screen patients susceptible to these 
ADRs. This study mainly focused on patients 
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Executive summary
Background
  HLA-B*1502 is a genetic predictor for Stevens–Johnson syndrome/toxic epidermal necrolysis caused by carbamazepine (CBZ) and 
phenytoin (PHT) among Han Chinese and south-east Asian populations, while HLA-A*3101 has recently been shown to associate with 
the full spectrum of CBZ-induced cutaneous adverse drug reactions (cADRs; maculopapular eruption, hypersensitivity syndrome and 
Stevens–Johnson syndrome/toxic epidermal necrolysis) in European and Japanese populations.
  With this knowledge we investigated whether HLA-A*3101 or any other common genetic marker was associated with lamotrigine- 
(LTG) or PHT-induced cADRs.
Results
  There was no association between HLA-A*3101 and LTG- or PHT-induced cADRs.
  We did not find a significant common genetic variant from our genome-wide analyses.
Conclusion
  We have shown that the association with HLA-A*3101 does not extend to LTG- or PHT-induced cADRs. We also did not detect any other 
significant common variants of association with LTG- or PHT-induced cADRs from genome-wide association studies.
  HLA-A*3101 thus appears to be a specific marker for CBZ-induced cADRs.
with the less severe MPE hypersensitivity 
reaction; however, there is a clear motivation 
to investigate whether HLA-A*3101 extends 
itself as a genetic marker for HSS and SJS/TEN 
caused by LTG and PHT. 
Conclusion
HLA-A*3101 does not appear to be a genetic 
marker for LTG- and PHT-induced MPE 
reactions in Europeans. The predictive 
application of HLA-A*3101 as a clinically 
relevant genetic marker for cADRs in Europeans 
appears to be specific to CBZ. 
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